Benzinga | Oct 20, 2021 08:24AM EDT

Craig-Hallum Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $45

Craig-Hallum analyst Robin Garner initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $45.